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Abstract
Multiple myeloma is a malignancy of immunoglobulin
producing plasma cells. Clinical features include bone pain due
to lytic bone lesions or pathological fractures, anemia,
symptomatic hypercalcemia, renal insufficiency, recurrent
infections and amyloidosis. In the last few years, there have been
considerable advances in the understanding of the biology of
this disease. While multiple myeloma is biologically diverse,
several oncogenes are activated in this illness. In addition, the
role of the bone marrow microenvironment to support the
growth and survival of the malignant cells has been well
described.  In this review, we discuss recent developments in
the molecular pathogenesis of myeloma. These recent
observations are being translated into novel therapeutic
approaches that target both the tumor cell as well as the stroma.
Current therapeutic strategies are discussed.
Introduction
Multiple myeloma is a hematological malignancy of
terminally differentiated plasma cells. Plasma cells develop from
B cells and produce antibodies in response to offending antigenic
stimulation. In most patients, the disease is restricted to sites
of active hematopoiesis within the axial skeleton, skull, ribs and
proximal regions of the long bones.1  The American Cancer
Society estimates that 14,600 new patients will be diagnosed
with myeloma and 10,900 will die in 2003 due to the disease in
the United States.2  The disease is more common in males and
its incidence is twofold higher in African Americans compared
to Caucasians.3 In 90% of patients, the plasma cells secrete a
monoclonal immunoglobulin (IgG 60%, IgA 10%, free light
chains 20%) with the remaining 10% of patients having non-
secretory myeloma.
Patients with multiple myeloma usually present with
symptoms related to the presence of lytic bone lesions, anemia,
renal failure and immunosuppression. Diagnosis is based on
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the presence of a triad of monoclonal immunoglobulin spike in
serum and/or urine, lytic bone lesions and bone marrow
plasmacytosis (>10%).4  A condition known as monoclonal
gammopathy of undetermined significance (MGUS) is relatively
common in patients older than 50 years (1-2%). While these
patients do not have myeloma and therefore do not require
therapy, they have an increased risk of developing myeloma and
require life-long follow-up.5
Etiology
Like most other tumors, the etiology of multiple myeloma
is unclear. Both environmental and genetic factors may have
important roles in its pathogenesis. Clustering of the disease
within families has been observed suggesting a genetic
predisposition.6, 7   The only environmental agents that are
clearly linked with myeloma are cigarette smoking, benzene and
radiation.8,9  Repeated or chronic antigen stimulation due to
recurrent or chronic infections and autoimmune disease has
been proposed as a possible risk factor. However, a large and
comprehensive study that included both Caucasians as well as
African Americans did not find any evidence for such an
association.10 The potential link between myeloma and human
herpes virus type 8 (HHV-8) has been debated for some time.11
While there is strong evidence for a causal association between
HHV-8, Castleman’s disease and primary effusion lymphoma,
a causal relation with myeloma has not been demonstrated.12
Multiple myeloma is similar to other tumors in that the
fundamental problem is a genetic one.  Using fluorescent in situ
hybridization (FISH) it is possible to document complex
chromosomal abnormalities in more than 50% of patients. With
more sensitive techniques, chromosomal abnormalities are
identified in almost 100% of patients.13 Karyotypic abnormalities
are non-random but different among myeloma patients. There
is also considerable heterogeneity within the same tumor
emphasizing the role of genetic instability in this disease.
Complex karyotypic abnormalities are the rule and complexity
increases with disease progression.3, 11 Primary translocations
occur early in the disease and are sometimes seen in MGUS
while secondary translocations are involved with progression.14
Primary translocations are simple, reciprocal translocations
that juxtapose an oncogene next to one of the immunoglobulin
(Ig) enhancers. These genetic errors occur either during IgH
class switching, during somatic hypermutation within germinal
centers or at the time of V(D)J recombination. Activated
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oncogenes include the cyclins D1, D2 and D3, fibroblast growth
factor receptor 3 (FGFR3), MMSET, c-MAF and MAFB.15,16-18
Secondary translocations usually involve c-MYC  and are
associated with enhanced cellular proliferation.3  In contrast to
most other tumors, p53 and Rb are not usually mutated in
patients with multiple myeloma.19, 20
The bone marrow stroma plays a critical role in supporting
the growth of the myeloma cells by supplying the supporting
matrix and production of growth and survival cytokines such
as IL-6 and insulin like growth factor 1 (IGF-1).21, 22  In turn, the
myeloma cells produce cytokines that can activate the
surrounding stroma (VEGF, IL-6) and osteoclasts (MIP-1α,
IL-1ß).23  VEGF is a growth and survival factor for myeloma cells
and stimulates marrow angiogenesis.24  Osteoclast activation is
responsible for the bone resorption and lytic lesions that are
found in around 75% of patients with the disease.25
Since the vast majority of patients with myeloma have a
detectable monoclonal protein, tumor cell kinetics has been very
well studied. Durie and Salmon measured the rate of paraprotein
synthesis by malignant plasma cells and thus determined the
tumor burden in patients with the disease. 26 Tumor burden is
the determining factor that guides decisions on when and whom
to treat.1, 27 It is estimated that a patient with advanced myeloma
has approximately 1012 malignant cells or about a kilogram of
disease.
Pathologically, the atypical, malignant plasma cells
proliferate and infiltrate the marrow in three different patterns
– either as multiple plasmacytomas of variable size, diffuse
marrow infiltration or a combination of the two.28, 29  Diffuse
marrow infiltration leads to significant osteoporosis due to
osteoclast activation while plasmacytomas activate bone
resorption locally leading to the formation of the typical lytic
bone lesions seen on routine skeletal surveys.
Patients with multiple myeloma are susceptible to recurrent
infections with gram-positive and gram-negative bacteria.
Often, they also fail to mount adequate immune responses to
vaccinations. These observations suggest that patients with
myeloma have profound defects in their immune system. 30  The
disease is associated with reduced levels of circulating normal
immunoglobulins due to both decreased synthesis and enhanced
catabolism. This antibody deficiency gets progressively worse
with advancing disease and independent of therapy. The
mechanisms behind the immunosuppression are not completely
understood.31, 32
Clinical Features, Staging and Prognosis
Clinical symptoms and signs occur either due to tumor mass
effects or cytokine/protein production by the tumor. Regional
tumor growth can cause compression neuropathies of the spinal
cord or peripheral nerves. Bone pain occurs due to vertebral
compression fractures at sites of osteopenia or lytic bone lesions
with the risk of pathological fractures. Patients are prone to
recurrent bacterial infections due to defects in the humoral arm
of the immune system (see above). Immunoglobulin light chains
can damage the kidneys in many ways. Deposition in the lumen
of the renal tubules leads to cast nephropathy while deposition
in the mesangium can lead to nephrotic syndrome and
progressive renal failure. Light chains are toxic to tubular cells
leading to renal tubular acidosis. In 15% of patients, light chains
are deposited in other tissues with the potential for cardiac, renal
and neurologic (polyneuropathy, autonomic neuropathy)
complications, a condition known as amyloidosis. The presence
of high concentrations of paraprotein in the blood may elevate
plasma viscosity enough to induce symptoms (hyperviscosity
syndrome). This is more often seen with IgA myeloma due to
the tendency of IgA to form polymers.
The malignant clone of cells suppresses normal
erythropoiesis in the bone marrow leading to anemia that is
often symptomatic. Postulated mechanisms underlying the
anemia are not completely understood but include lack of
erythropoietin (EPO) due to any associated renal dysfunction,
production of suppressive cytokines, and bleeding.
Bleeding and thrombotic symptoms are uncommon
presenting features of the disease. They are thought to be due
to amyloid deposition in blood vessels, acquired deficiency in
pro-coagulant factors such as Factor X or anticoagulant proteins
such as Protein C.
When myeloma is suspected, a diagnostic work-up to
confirm or rule out the disease is necessary. At a minimum,
complete blood count, blood smear examination, serum calcium
and creatinine, serum and urine special protein electrophoresis,
bone marrow aspirate and biopsy as well as radiographic
examination of the axial skeleton should be performed.
Additional studies such as circulating plasma cells, labeling
index, flow cytometry, chromosomal studies, ß
2
-microglobulin,
lactate dehydrogenase and C-reactive protein assist in
prognostication. 33, 34  The disease can only be diagnosed if
established criteria are present, and care must be taken not to
misdiagnose MGUS as active myeloma. 4  The role of magnetic
resonance imaging as well as positron emission tomography in
the initial evaluation of the disease is not clear at present. 29, 35
Biologically, myeloma is a very heterogeneous tumor and
the course of the disease varies considerably among patients.
The median survival is 3 years, but patients may survive from
less than 1 year to more than 10 years from diagnosis. Prognosis
depends on the disease burden, and only patients with
symptomatic disease require therapy. Thus, a staging system
has been developed that categorizes patients into 3 stages that
correlate well with disease burden, and determine the need for
therapy. 26, 36 The two most important prognostic factors at the
time of diagnosis are the serum levels of ß
2
-microglobulin and
albumin. Additional prognostic factors include C-reactive
protein, high levels of circulating plasma cell, elevated plasma
cell labeling index, monosomy or deletion of chromosome 13,
bone marrow micro vessel density and elevated serum
syndecan-1 levels. 33, 34
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Current therapy for multiple myeloma
At the Mayo Clinic, patients with plasma cell disorders are
classified into 4 categories: MGUS, smoldering multiple
myeloma (sMM), indolent multiple myeloma (IMM) and
symptomatic multiple myeloma (SMM). 37  Not all patients with
myeloma require therapy; SMM must be distinguished from
MGUS and indolent/smoldering myeloma. Patients should only
be treated if they have symptoms or active disease. Patients with
SMM usually are in Durie-Salmon Stage II or III (defined by
any of the following: hemoglobin < 10g/dl, serum IgG > 5g/dl,
serum IgA > 3g/dl, elevated serum calcium, urine monoclonal
protein excretion > 4g/24 hours, or the presence of lytic bone
lesions) and require immediate therapy. The therapeutic
armamentarium available to treat myeloma has been steadily
increasing.
Pharmacotherapy
Once a decision to treat has been taken, the major
determinant of therapy is whether the patient is a candidate for
high dose chemotherapy with autologous peripheral blood stem
cell transplant (PBSCT) since survival is improved with this
approach. 38  Patients who are eligible for PBSCT should not be
given alkylator therapy because these drugs damage bone
marrow progenitor cells and compromise stem cell harvest.
Patients who are not eligible for PBSCT should be treated with
standard therapy. For many years, the mainstay of therapy has
been alkylating agents such as melphalan or cyclophosphamide
combined with glucocorticosteroids giving response rates of
50%. However less than 10% of patients achieve a complete
response, and the median survival is 3 years. Responses are
classified as complete, partial, stable or progression based on
the results of serum M protein, symptoms and bone marrow
plasmacytosis. More complex chemotherapy regimens lead to
higher response rates but survival is not improved. 1, 27
Patients who will undergo PBSCT are usually treated with 3
or 4 cycles of combination chemotherapy such as vincristine,
doxorubicin and dexamethasone (VAD). However,
dexamethasone by itself may be as effective and better tolerated.
Relatively healthy patients are often treated with dexamthesone
40mg per day from days 1 to 4, 9 to 12, 17 to 20 with an 8-day
treatment free period. Therapy is repeated every 28 days.
Autologous stem cells are harvested after high dose
cyclophosphamide and G-CSF. Patients are then treated with
high dose melphalan (200mg/m2) in an attempt to ablate the
malignant clone followed by the infusion of the autologous stem
cells to reconstitute normal hemopoiesis. This approach is
associated with response rates of up to 90% and an improved
survival but is not curative. The survival curves do not plateau
and patients continue to relapse and often die of their disease.38
The role of back-to-back “tandem” transplants has been debated
for some time. The procedures seem to be relatively well
tolerated in select patients and are associated with an acceptable
mortality rate (~3%) leading to higher response rates and
improved survival. 39 Recently, the French Myeloma Group has
reported their experience with tandem autologous transplants
for myeloma. While this study clearly demonstrates a superior
outcome following tandem transplants, it appears that patients
who have a complete or very good partial response within 3
months of their first transplant have a good outcome and can
be safely observed. A second transplant is possible if they
progress assuming that enough stem cells were collected in the
first harvest.40
Autologous stem cell harvests are invariably contaminated
with malignant plasma cells and contribute to relapse of the
disease.41, 42 Purging of the harvested cells does not lead to
improved outcomes implying that high dose therapy is not
eradicating the malignant clone.43  In an attempt to eliminate
stem cell contamination and stimulate a graft versus myeloma
effect, allogeneic bone marrow transplantation (BMT) has been
performed in eligible patients. The procedure can lead to
prolonged disease free survival in a select group of patients but
is associated with a 30% mortality and significant graft versus
host disease in the survivors.44 Thus, allogeneic BMT is
considered experimental therapy and patients are treated in the
context of clinical trials.
Patients with lytic bone lesions are now routinely treated
with bisphosphonates (pamidronate or zoledronic acid) to
prevent or delay progression of skeletal complications.45 While
interferon is often advocated for therapy of myeloma, it is not
often used in the United States, and its efficacy is very limited.46
Although the disease is often responsive to first line therapy,
it invariably progresses and patients require further therapy.
Thalidomide has proven efficacy against the disease even among
heavily pretreated patients and in general is well tolerated.47
The drug interferes with myeloma cells and the surrounding
stroma through a variety of mechanisms.48 It is usually started
at 100mg daily given at bedtime and increased as tolerated. Most
patients respond to a dose of 200 – 300mg per day. Due to its
well-known teratogenicity, patients must be educated on its use,
undergo regular phone surveys, and every prescription requires
authorization. Common side effects include somnolence,
constipation, peripheral neuropathy, rashes and deep vein
thrombosis especially when combined with dexamethasone. The
drug is now being used for initial control of the disease and does
not compromise responses to high dose chemotherapy and
PBSCT or stem cell collection.49
Recently, the Food and Drug Administration approved
bortezomib (Velcade®) for patients with refractory disease.
Bortezomib is a proteasome inhibitor, preventing the normal
function of this enzyme complex in degrading cellular proteins
that are involved in regulation of the cell cycle.50  Up to a third
of patients are expected to have a response with a median
duration of 12 months.51 Additional drugs based on thalidomide
(IMiDs), NF-kB inhibitors (PS-1145), arsenic trioxide and 2-
methoxyestradiol are undergoing clinical trials in patients with
the disease.48, 50, 52
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Radiation Therapy
Plasma cells are very sensitive to radiation although the
mechanisms underlying their sensitivity to this therapeutic
modality are not clear. External beam radiation has been used
for many years to treat localized plasmacytomas with excellent
local control.53 Local radiation therapy is used in patients with
myeloma to control pain from lytic bone lesions, symptomatic
soft tissue masses and to treat spinal cord compression.54 Thus,
there has been considerable interest in the use of total body
irradiation (TBI) as part of the conditioning regimen prior to
stem cell transplantation. The largest study to date has been
performed by the French Myeloma Group (IFM) and they
showed that combining TBI with high dose melphalan is not
superior to high dose melphalan alone; the combined regimen
is associated with higher toxicity.55 Thus TBI has gone out of
favor for conditioning and radiation therapy is used only for
palliative control.
Experimental therapy for myeloma
The poor prognosis of patients with myeloma has
prompted the exploration of new therapeutic approaches for
the disease. Progress in the fields of immunology, tumor biology
and virology over the past few years has paved the way for
considerable advances in the future. Since myeloma cells express
a single type of antibody, this might appear as the perfect tumor
specific antigen. Thus there is considerable interest in
immunotherapy for the disease using expression of co-
stimulatory molecules, generation of tumor cell specific T-cell
responses as well as antibody based therapy such as Rituximab
(Rituxan®).56-58  Recently, myeloma cells were shown to express
high levels of CD52.59  Thus, the disease might respond to
alemtuzumab, Campath 1H (a monoclonal antibody directed
against CD52) and clinical trials are about to start.
In the last few years there has also been considerable
interest in the use of gene therapy for this disease. Therapeutic
approaches have included the expression of co-stimulatory
molecules, secretion of immune activating cytokines and
expression of suicide genes in combination with their respective
substrates. 60 Recent work has led to the development of tumor
virotherapy whereby replicating viruses are used as antitumor
weapons. Replicating viruses seem to preferentially infect and
multiply in tumor cells. The selective replication of the virus in
tumor cells induces cell death with progeny virus infecting
surrounding tumor cells leading to local viral amplification. Our
work has focused on the use of a vaccine strain of measles virus
that has potent and selective oncolytic activity against
myeloma.61 Recently we have engineered a recombinant measles
virus that induces expression of the thyroidal sodium iodide
symporter (NIS) in tumor cells. These cells take up radioiodine
allowing the non-invasive tracking of viral replication and gene
expression in vivo. NIS expression also enhances the oncolytic
effect of the virus by combining it with 131I that decays by the
emission of electrons (beta particles) that induce cell death. 62
This vector is expected to undergo clinical trials in the
near future.
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